Biogen shares soar on Alzheimer's drug developments
September 28, 2022 at 10:16 AM EDT
A study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over an 18-month period.
 |
||||||||||||
|
||||||||||||
| About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map | ||||||||||||
Photos copyright by Jay Graham Photographer
